Batavia Biosciences Joins iAds – Intelligent Design of Adenovirus Vectors Program 

The iAds consortium brings together 6 partners from 5 European countries and aims to apply a disruptive approach for viral vector design.
Batavia Biosciences - Favicon

Leiden, March 7, 2024 – Batavia Biosciences, a leading contract development and manufacturing organization, is excited to announce its active engagement in the iAds – Intelligent design of Adenovirus vectors program. The iAds consortium brings together 6 partners from 5 European countries and aims to apply a disruptive approach for viral vector design. This strategic involvement underscores Batavia Biosciences’ commitment to advancing state-of-the-art research and fostering collaborations that drive innovation within the viral vector field. 

Gene therapy is emerging as a promising therapeutic approach to address many areas of currently unmet medical need, such as neurodevelopmental, or neurodegenerative disorders and cardiovascular diseases. A frequently used vector in these development programs is the adenoviral vector. In the iAds program, new adenoviral vectors will be developed with improved targeting of the cardiovascular or central nervous systems to overcome limitations imposed by the patient’s immune system and from off-target effects.

The iAds consortium brings Batavia Biosciences together with IGMM, Janssen Vaccines, CNB-CSIC, Umeå University and the University of Edinburgh and combines their expertise in structural biology, receptor biology, clinical gene transfer, immunology, vaccines and GMP manufacturing to establish a disruptive approach to viral vector design.

Batavia Biosciences has a long-standing track record in the development and manufacturing of viral vectors such as the adenovectors and is an integral player in the cell and gene therapy field. Its extensive experience in bioprocess development and industrial scale manufacturing will be leveraged to develop a manufacturing process for this new generation of adenovirus vectors and produce research batches for pre-clinical testing. This way Batavia aims to accelerate and streamline the development trajectory from early-stage discovery into the clinic.

Wilfried Bakker, Director Science & Innovation at Batavia Biosciences, adds: “This collaboration highlights our commitment to advancing scientific knowledge and reinforces our position as a center of excellence in the viral vector field.”

About iAds 

iAds, a European Innovation Council (EIC) Pathfinder project, aims to maximize the potential of adenovirus vector for vaccines and gene transfer. This project is made possible in part by a contribution from the European Innovation Council under the grant agreement No 101098647.

For more information, please visit www.intelligentadenoviruses.eu

Related

New Test for Rapid and Low-cost Quality Control for Polio Vaccines

Batavia Biosciences has developed a qPCR method that can specifically detect mutations that can accumulate in poliovirus strains during vaccine production. The test demonstrates a sensitivity level highly comparable to current best practices. The novel test has been accepted for publication in the international, peer-reviewed prestigious Vaccine journal.

Viral Vector Production Guide

Bringing a new viral vector-based therapy from lab to market? This resource guides you through the complexities of viral vector development, scale-up, and cGMP manufacturing.

Low-cost viral vector manufacturing

High-throughput screening for viral vectors

Viral vector manufacturing

Thermostable viral envelope protein formulation

Maximizing protein expression